Korea approves revised Phase 2/3 trial plan for EGMCV4 meningococcal vaccine
Regulators approved a revised Phase 2/3 trial plan for EGMCV4, a meningococcal vaccine from Egene, in Korea on November 12, 2026.
185490 · KOSDAQ · Based on DART filings
2 total · 20 per page
Regulators approved a revised Phase 2/3 trial plan for EGMCV4, a meningococcal vaccine from Egene, in Korea on November 12, 2026.
The company applied to the MFDS on 2026-11-10 to amend the Korean Phase 2/3 trial plan for its quadrivalent meningococcal vaccine EG-MCV4.
Get app alerts for new disclosures from EyeGene,Inc.